Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sorafenib + gemcitabine + interferon
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Oral, Intravenous, Subcutaneous, Intramuscular
01
Overview
This is a combination regimen consisting of three drugs: - **Sorafenib** is an oral small molecule multikinase inhibitor that targets RAF kinases (including BRAF), vascular endothelial growth factor receptors (VEGFR), and platelet-derived growth factor receptor beta (PDGFR-β). It inhibits tumor cell proliferation via the RAF/MEK/ERK pathway and reduces angiogenesis by blocking VEGFR and PDGFR signaling[8]. - **Gemcitabine** is a nucleoside analog used as chemotherapy. It incorporates into DNA during replication, causing chain termination and apoptosis in rapidly dividing cells. - **Interferon** refers to interferons such as interferon-alpha; these are cytokines with immunomodulatory effects that can enhance anti-tumor immune responses. This combination has been explored in clinical trials for advanced cancers such as pancreatic cancer and renal cell carcinoma. The rationale for combining these agents lies in their complementary mechanisms—targeting tumor proliferation pathways (sorafenib), direct cytotoxicity to dividing cells (gemcitabine), and immune modulation (interferon)[2][3]. However, evidence for efficacy remains limited or inconclusive.
- Brand names
- nexavarintron a
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)DNADNA polymerase familyVEGFR-1 (Vascular endothelial growth factor receptor 1)FLT3 (Fms related receptor tyrosine kinase 3)VEGFR4 (Vascular endothelial growth factor Receptor-3)IFNAR (Immune system modulation via type I interferon receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)RAF1 (c-Raf-1 (Y340D/Y341D))RET (Rearranged during transfection receptor tyrosine kinase)RNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on sorafenib + gemcitabine + interferon.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sorafenib + gemcitabine + interferon.